Результаты поиска

Long Term Survival of Pathological Thoracolumbar Fractures Treated with Vertebroplasty: Analysis Using a Nationwide Insurance Claim Database.

BACKGROUND: There are still debates on the long-term outcome of treating pathological thoracolumbar fractures, including osteoporosis and oncologic problems, using vertebroplasty. METHODS: We collected 8625 patients with pathological thoracolumbar fractures (ICD-9-CM codes 733.13 combined with 805.2 or 805.4) between the years of 2003 to 2013, from the two million random samples from the National Health Insurance Research Database in Taiwan. Survival analysis was conducted to estimate the mortality risks of different treatments, including vertebroplasty (n = 1389), conventional open surgery (

Совпадение в полном тексте источника
… Kallmes D.F., Comstock B.A., Heagerty P.J., Turner J.A., Wilson D.J., Diamond T.H., Edwards R., Gray L.A., Stout L., Owen S., et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N. Engl. J. Med. 2009;361:569–579. doi: 10.1056/NEJMoa0900563. 16. … Clark W., Bird P., Gonski P., Diamond T.H., Smerdely P., McNeil H.P., Schlaphoff G., Bryant C., Barnes E., Gebski V. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): A multicentre, randomised, double-blind, placebo-controlled trial. …

От эмпирического лечения к точному вмешательству: библиометрический анализ нейропсихиатрической системной волшебной системы с использованием нескольких баз данных (Erithematosus)2006-2025).

ЦЕЛЬ: Нейропсихиатрическая системная волчанка (NPSLE) представляет собой серьезное и сложное осложнение системного волчанка, которое влияет на принятие диагностических решений и стратегии лечения. Однако временнóе развитие основанных на фактических данных диагностических и терапевтических парадигм, а также сохраняющиеся клинические узкие места не были в полной мере охарактеризованы. МЕТОДЫ: Мы провели всеобъемлющий библиометрический анализ 1,569 Публикации, связанные с ЯИЭ, взяты из " Web of Science Core Collection " и " Scopus " 2006 и 2025. Кроме того, были включены соотв

Совпадение в полном тексте источника
… PMID: 26779811 PMC4742415 37 Suurmond J Diamond B . Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity . J Clin Invest . ( 2015 ) 125 : 2194–202 . doi: 10.1172/jci78084 . PMID: 25938780 PMC4497746 38 Ramos PC Mendez MJ Ames PR Khamashta MA Hughes GR . … PMID: 31851795 43 Gupta R Agapoff M Diamond B . Neuropsychiatric systemic lupus erythematosus - current and novel treatments . Curr Opin Rheumatol . ( 2026 ) 38 : 115–20 . doi: 10.1097/bor.0000000000001141 . PMID: 41251208 PMC12863625 44 Hanly JG Urowitz MB Su L Bae SC Gordon C Wallace DJ . …

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.

The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-equipped for future pandemics. While unprecedented strides have been made developing vaccines and treatments for COVID-19, there remains a need for highly effective and widely available regimens for ambulatory use for novel coronaviruses and other viral pathogens. We posit that a priority is to develop pan-family drug cocktails to enhance potency, limit toxicity, and avoid drug resistance. We urge cocktail development for all viruses with pandemic potential both in the short term (<1 to 2 years) and longer term wi

Совпадение в полном тексте источника
… Bekerman E, Neveu G, Shulla A, Brannan J, Pu S-Y, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, Govero J, Nagamine CM, Diamond MS, De Jonghe S, Herdewijn P, Dye JM, Randall G, Einav S. 2017. … Son J, Huang S, Zeng Q, Bricker TL, Case JB, Zhou J, Zang R, Liu Z, Chang X, Harastani HH, Chen L, Castro MFG, Zhao Y, Kohio HP, Hou G, Fan B, Niu B, Guo R, Rothlauf PW, Bailey AL, Wang X, Shi P-Y, Martinez ED, Whelan SPJ, Diamond MS, Boon ACM, Li B, Ding S. 2020. …

Association Between Survival Benefits of Anticancer Drugs and Probability of US Food and Drug Administration Approval: A Systematic Review.

BACKGROUND AND OBJECTIVES: Survival benefit constitutes the primary pillar of therapeutic efficacy in oncology. However, the survival benefits observed in registrational trials broadly range from significant to marginal, even for US Food and Drug Administration (FDA)-approved drugs. This study explores the association between survival benefits and the likelihood of FDA approval and estimates the boundary effect size that distinguishes FDA-approved from non-approved drugs.MethodsWe screened 3463 phase 3 trials initiated between 1990 and 2021 on ClinicalTrials.gov. Eligibility was restricted to

Совпадение в полном тексте источника
… Diamonds represent the pooled mean, with the points of the diamonds representing 95% CIs. …

Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.

Great progress in the treatment of patients with multiple myeloma (MM) has been made due to the development of novel drugs. Patients with relapsed/refractory MM (RRMM) can be enrolled in early-phase clinical trials, but their performance across the last decade is unknown. We conducted a meta-analysis on the overall response rate (ORR) and toxicity. PubMed, Embase, and Cochrane Library were systematically searched for phase I and phase II trials investigating an experimental compound as a single agent or in combination with dexamethasone, published from January 1, 2010 to July 1, 2020. Eighty-e

Совпадение в полном тексте источника
… The points of the diamond indicate the 95% CI of the pooled mean. The horizontal line at the bottom indicates the prediction interval. Blank lines indicate missing information from the trial paper. *The study population in Chen et al. 84 included two patients with Waldenström’s Macroglublinemia. … The points of the diamond indicate the 95% CI of the pooled mean. The horizontal line at the bottom indicates the prediction interval. Blank lines indicate missing information from the trial paper. …

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.

Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor prognosis, with a median OS of between 4 and 6 months. Nuclear export inhibition, specifically inhibition of CRM1/XPO1, is an emerging novel treatment modality that has shown promise in treatment-refractory MM. Initially discovered in yeast in 1983, early clinical applications were met with significant toxicities that limited their utility. The cr

Совпадение в полном тексте источника
… Golombick T, Diamond T, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. … Ramakrishna R, Diamond T, Alexander W, Manoharan A, Golombick T. Use of curcumin in multiple myeloma patients intolerant of steroid therapy. Clin Case Rep. 2020;8(4):739–744. doi: 10.1002/ccr3.2735. 27. Bolger G, Licollari A, Bagshaw R, Tan A, Greil R, Vcelar B, et al. …

Long-Term Survival with Multiple Myeloma: An Italian Experience.

Background/objectivesTreatments for multiple myeloma (MM) have expanded in the last decade, and the overall survival (OS) of MM patients (pts) is in continuous improvement. With the availability of new treatments and the use of high-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation (ASCT), the median OS of newly diagnosed MM (NDMM) pts is 6-8 years. To date, approximately 50% and 28% of MM patients are still alive at 5 years and 10 years. Few data are reported concerning the characteristics of the long-term survival MM pts.Methodsthe aim of this observational mu

Совпадение в полном тексте источника
… Meseha M., Hoffman J., Kazandjian D., Landgren O., Diamond B. Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions. Curr. Oncol. Rep. 2024;26:679–690. doi: 10.1007/s11912-024-01537-2. 34. Szalat R., Anderson K., Munshi N. … Maura F., Rajanna A.R., Ziccheddu B., Poos A.M., Derkach A., Maclachlan K., Durante M., Diamond B., Papadimitriou M., Davies F., et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J. Clin. Oncol. 2024;42:1229–1240. doi: 10.1200/JCO.23.01277. 38. …

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis when treated with cytotoxic chemotherapy. We report the findings of a phase 2 study evaluating a chemotherapy-free combination of romidepsin plus lenalidomide as initial treatment for patients with PTCL who were aged >60 years or noncandidates for chemotherapy. Treatment was initiated with romidepsin 10 mg/m2 IV on days 1, 8, and 15 and lenalidomide 25 mg taken orally from days 1 to 21 of 28-day cycle for up to 1 year. The primary objective was overall response rate (ORR). Secondary objectives included safety and survival.

Совпадение в полном тексте источника
… Green diamond denotes stem cell transplant, yellow cross denotes subsequent cytotoxic chemotherapy, green asterisk denotes time to best response, black cross denotes disease progression, gray circle denotes study withdrawal or lost to follow-up, and black diamond denotes death. “//” stands for axis break …

Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.

OBJECTIVE: The purpose of this project was to determine the role of corneal implants in the management of corneal thinning disease condition … ive surgeons. It involves creating tunnels in the corneal stroma to secure the implants either by a diamond knife or laser calibrated to an approximate depth of 70% of the cornea. Variable approaches have been employed by surgeons in selecting ring segment size, number and position. Generally, two segments of equal thickness are placed superiorly and infe …

Hypercalcemia as a Presenting Clinical Manifestation of Adenocarcinoma of the Colon.

Hypercalcemia is rarely associated with colon cancer. It is related to overexpression of parathyroid hormone-related protein (PTH-rp) in malignant cells of the primary colon tumor and metastases. A 44 year old lady presented for evaluation of severe hypercalcemia (15.7 mg/dL) associated with abdominal pain, nausea and constipation. She was diagnosed with metastatic colon cancer involving the liver. Therapy for hypercalcemia consisted of intravenous bisphosphonate and saline hydration. Hypercalcemia remained resistant and refractory to treatment despite resection of the colon tumor. She died so

Совпадение в полном тексте источника
… AH Cadeau SD Bertrand GM Guerin-Meyer VI Gamelin EC Audran MJ Humoral hypercalcemia in patients with colorectal carcinoma: report of two cases and review of the literature Cancer 1999 86 11 2217 2221 10.1002/(SICI)1097-0142(19991201)86:11<2217::AID-CNCR7>3.0.CO;2-V 10590360 7 Links M Ho H Clingan P Diamond …

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

PURPOSE: The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease for whom prospective trials are limited, aiming to induce minimal residual disease (MRD) negativity. METHODS: This academic, investigator-initiated, multicenter, phase II trial enrolled patients with high-risk NDMM (HRNDMM) defined by mandatory International Staging System stage II/III combined with del17p, t(4;14), t(14;16), or more t

Совпадение в полном тексте источника
… Diamond B Ziccheddu B Maclachlan K : Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures . Blood 141 : 2359 - 2371 , 2023 36626250 10.1182/blood.2022018244 PMC10273163 34. … Maura F Weinhold N Diamond B : The mutagenic impact of melphalan in multiple myeloma . Leukemia 35 : 2145 - 2150 , 2021 34012133 10.1038/s41375-021-01293-3 36. …

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.

The outcome of multiple myeloma (MM) has significantly improved in the last few decades due to several factors such as new biological discoveries allowing to better stratify disease risk, development of more effective therapies and better management of side effects related to them. However, handling all these aspects requires an interdisciplinary approach involving multiple knowledge and collaboration of different specialists. The hematologist, faced with a patient with MM, must not only choose a treatment according to patient and disease characteristics but must also know when therapy needs t

Совпадение в полном тексте источника
… Maura F., Rajanna A.R., Ziccheddu B., Poos A.M., Derkach A., Maclachlan K., Durante M., Diamond B., Papadimitriou M., Davies F., et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J. Clin. Oncol. Off. J. Am. Soc. Clin. … Maura F., Boyle E.M., Coffey D., Maclachlan K., Gagler D., Diamond B., Ghamlouch H., Blaney P., Ziccheddu B., Cirrincione A., et al. Genomic and Immune Signatures Predict Clinical Outcome in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens. Nat. …

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies. Only 22% would have met eligibility for MagnetisMM-3 cohort A. The overall response rate (ORR) was 65%, including ≥CR in 36%. Median progression-free

Совпадение в полном тексте источника
… Kowalski A Lykon J Diamond B Coffey D Kaddoura M Maura F Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies Blood Adv 2025 9 4979 86 10.1182/bloodadvances.2025016911 40590849 PMC12514479 Kowalski A, Lykon J, Diamond B, Coffey D, Kaddoura M, Maura F, et al. …

The role of vitamin D in hematologic disease and stem cell transplantation.

Vitamin D is a steroid hormone with a broad range of biological effects ranging from the classical role as a mediator of calcium and phosphate balance to cellular differentiation and immune modulation. These effects impact normal and dysfunctional hematopoietic and immune function, which may allow an avenue for improved treatment and support of patients suffering from hematologic disorders. In this review, we will summarize the role of vitamin D in normal hematopoiesis, discuss ways in which vitamin D may improve outcomes, and discuss a potential role of vitamin D for treating hematologic diso

Совпадение в полном тексте источника
… Diamond and colleagues in New South Wales followed a group of myeloma patients for 10 years and stratified them into quartiles by serum vitamin D concentration. … Diamond T. Golombick T. Manoharan A. Vitamin D status may effect the skeletal complications of multiple myeloma Am. J. Hematol. 2010 85 302 303 20162545 10.1002/ajh.21619 …

Концептуализация комплексного ухода за многими миеломами: роль питания, дополнительных услуг и дополнительных услуг.

Множественная миелома (ММ) — вторая по распространенности гематологическая гелингология, масштабы которой в последние годы значительно возросли. Прогноз ММ радикально изменился с введением новых лекарственных средств, повышающих ожидаемую продолжительность жизни; рецидивы являются обычным явлением во время болезни и характеризуются увеличением числа отказов от лечения. Кроме того, пациенты ММ сталкиваются с проблемами, связанными с качеством жизни, в то время как обычное лечение может быть ограничено. Это включает боль в костях и диализ из-за осложнений острой почечной недостаточности. Поэтому

Совпадение в полном тексте источника
… Golombick T., Diamond T.H., Manoharan A., Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study. Am. J. … Ramakrishna R., Diamond T.H., Alexander W., Manoharan A., Golombick T. Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy. Clin. Case Rep. 2020;8:739–744. doi: 10.1002/ccr3.2735. 56. …

Impact of Oncology Patients’ Knowledge and Awareness on Emergency Visits and Hospital Admissions: A Cross-Sectional Study

INTRODUCTION: Chemotherapy remains a cornerstone of cancer treatment, but is frequently accompanied by adverse effects that can affects patients' quality of life. In Saudi Arabia, patients' understanding of chemotherapy regimens and related toxicities is not well characterized. This study aimed to evaluate chemotherapy awareness among cancer patients and examine its association with hospital admissions and emergency department (ED) visits. METHODS: This cross-sectional descriptive study was conducted at a tertiary hospital in Saudi Arabia, between year of 2022 to 2023. Adult cancer patients r

Совпадение в полном тексте источника
… likely to report difficulties understanding medical information and adverse medication reactions, even when treated by language-concordant physicians (adjusted OR 3.2 and 2.3, respectively), underscoring persistent comprehension gaps despite interpreter or bilingual support. 16 Likewise, a study by Diamond … Diamond L, Izquierdo K, Canfield D, Matsoukas K, Gany F. A systematic review of the impact of patient-physician non-English language concordance on quality of care and outcomes. J Gen Intern Med . 2019;34(8):1591–1606. doi: 10.1007/s11606-019-04847-5 18. Chen DW, Banerjee M, He X, et al. …

Preventing osteolytic lesions and osteomyelitis in multiple myeloma.

Multiple myeloma is a hematological malignancy affecting the plasma cells. It is the second most common hematologic cancer in adults. Over 90% of patients develop local osteolytic lesions and skeletal-related events at some point during the progression of the disease. Bone lesions can induce severe pain and immobility and can also increase the risk of fractures and osteomyelitis. Skeletal complications are associated with poor clinical outcomes, affecting quality of life and mortality. Current standards of care for myeloma, e.g., autologous stem-cell transplantation (ASCT) and chemotherapy, do

Совпадение в полном тексте источника
… Diamond et al. (2021) also tested oral lenalidomide (10 mg) given on days 1–21 of a 28-day cycle continuously until progression or intolerance for up to five years in patients with multiple myeloma. … Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis Adv Ther 37 7 2020 3404 3416 32524500 10.1007/s12325-020-01395-x PMC7467415 65 Diamond B. Korde N. …

Traditional herbal medicine for the prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis with association rule analysis.

IntroductionThis systematic review and meta-analysis evaluated the preventive efficacy and safety of orally-administered traditional herbal medicine (THM) for the management of chemotherapy-induced peripheral neuropathy (CIPN) in patients with cancer.MethodsRandomized controlled trials (RCTs) evaluating the efficacy of orally-administered THM in the prevention of CIPN published up to 30 April 2024 were retrieved from nine databases. The primary outcome was the incidence of CIPN, and the secondary outcomes included changes in neuropathic pain intensity, nerve conduction study parameters, Karnof

Совпадение в полном тексте источника
… The overall effect size is represented by a diamond, indicating a risk ratio of 0.83 [0.74, 0.93]. The heterogeneity is high with I² at 91%, and the p-value for the overall effect is 0.001. TABLE 2 Summary of findings. … Diamonds represent pooled results, indicating overall effectiveness, with values favoring either control or THM. Sensory subgroup shows a mean difference of 3.77, while the motor subgroup shows 2.48, both with respective confidence intervals. …

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B-Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community-Based Centers and for Outpatient Step-Up Dosing.

INTRODUCTION: Safe outpatient delivery of B-cell maturation antigen-targeting bispecific antibodies (BCMA-BsAbs) in multiple myeloma (MM) is challenging, particularly during step-up dosing (SUD). Standardized guidance for European community practice is limited. METHODS: A modified Delphi methodology panel sought expert consensus on safe, effective outpatient SUD and transition of care from academic to community centers for patients receiving BCMA-BsAbs. A steering committee of 10 European specialists in MM and BCMA-BsAb delivery generated statements based on literature review and clinical exp

Совпадение в полном тексте источника
… Diamond I. R., Grant R. C., Feldman B. M., et al., “Defining Consensus: A Systematic Review Recommends Methodologic Criteria for Reporting of Delphi Studies,” Journal of Clinical Epidemiology 67, no. 4 (2014): 401–409, 10.1016/j.jclinepi.2013.12.002. 16. Gattrell W. T., Logullo P., van Zuuren E. … Kowalski A., Lykon J., Diamond B., et al., “Tocilizumab Prophylaxis for Patients With Multiple Myeloma Treated With Bispecific Antibodies,” Blood Advances 9, no. 19 (2025): 4979–4986, 10.1182/bloodadvances.2025016911. 31. Scott S. A., Roberts D. L., Gupta V. …

Экономическое бремя лечения раковых заболеваний в частном страховом населении Ливана: a seven- Ретроспективный когортный анализ (год)2018-2024).

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Рак создает растущее экономическое бремя для систем здравоохранения во всем мире, однако в странах с низким и средним уровнем дохода по-прежнему ощущается нехватка продольных данных о расходах на лечение раковых заболеваний на уровне населения в рамках частного страхования. Частный страховой сектор Ливана, находящийся в ведении администраторов третьих сторон, охватывает значительную долю экономически активного населения, однако ни одно из опубликованных исследований не характеризовало его экономического бремени, связанного с раком, в том числе во время экономического спа

Совпадение в полном тексте источника
… Panel (C) Age-stratified pooled patient counts (2018–2024, left axis, bars) and 2024 crude cancer patient rates per 100,000 insured members (right axis, diamonds), illustrating the steep age gradient in both patient volume and cancer patient rates. … Panel C is a horizontal bar chart that presents costs and patient numbers for five cancer types within a high-cost cohort, using separate bars and diamond markers. Panel D is a horizontal bar chart indicating the share of total cohort spending by population quintile. …